Edit |   |
---|---|
Antigenic Specificity | CD27/TNFRSF7 (Varlilumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Varlilumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD27/TNFRSF7, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others. |
Immunogen | n/a |
Other Names | Varlilumab, CD27/TNFRSF7, 1393344-72-3 |
Gene, Accession # | CAS: 1393344-72-3 |
Catalog # | abx831311 |
Price | please inquire |
Order / More Info | CD27/TNFRSF7 (Varlilumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950